{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:46:32Z","timestamp":1779212792691,"version":"3.51.4"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold> The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of ARNI in HFmrEF patients.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> From inception to 15 February 2022, articles were searched <jats:italic>via<\/jats:italic> PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Whip, and Wanfang databases. Left ventricular functions, indicators related to HF, quality of life score, 6-Minute Walk Test, total effective rate, mortality, readmission rate, and adverse events were the outcomes. Relative risk (RR), weighted mean difference (WMD), and 95% confidence interval (CI) were used to evaluate the outcomes. The heterogeneity test was conducted for each indicator and measured by I<jats:sup>2<\/jats:sup> statistics. Subgroup analysis was performed regarding the type of study and duration of treatment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Sixteen studies involving 1,937 patients were included in this study. Our results showed ARNI was likely to improve left ventricular function by increasing the left ventricular ejection fraction (LVEF) (WMD: 2.36, 95%CI: 1.09\u20133.62), stroke volume (WMD: 16.800, 95%CI: 11.385\u201322.215), and left ventricular short-axis shortening rate (WMD: 2.05, 95%CI: 0.25\u20133.86), decreasing left ventricular end-diastolic dimension (WMD: \u22122.48, 95%CI: \u22123.83 to \u22121.13), left atrial diameter (WMD: \u22122.23, 95%CI: \u22122.83 to \u22121.63), C-reactive protein level (WMD: \u22121.40, 95%CI: \u22122.62 to \u22120.18), and N-terminal-pro B-type natriuretic peptide level (WMD: \u2212494.92, 95%CI: \u2212641.34 to \u2212348.50). ARNI has a higher total effective rate (RR: 1.15, 95%CI: 1.08\u20131.21), Kansas City cardiomyopathy questionnaire (WMD: 4.13, 95%CI: 3.46\u20134.81), and 6-Minute Walk Test (WMD: 51.35, 95%CI: 26.99\u201375.71) compared with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). In addition, ARNI decreased the readmission rate (RR: 0.54, 95%CI: 0.43\u20130.68) (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05). Nevertheless, there were no significant differences in the adverse outcomes.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This meta-analysis suggests ARNI may be an effective strategy with which to improve the left ventricular function, and quality of life, and reduce the readmission rate in HFmrEF patients. However, long-term clinical studies with large samples are still needed to further explore the efficacy and safety of ARNI compared with ACEI or ARB in the HFmrEF population.<\/jats:p>","DOI":"10.3389\/fphar.2022.982372","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T08:05:41Z","timestamp":1666598741000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jianbin","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruizhen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1755-7682-7-50","article-title":"Serum C-peptide assay of patients with hyperglycemic emergencies at the Lagos State University Teaching Hospital (LASUTH), Ikeja","volume":"7","author":"Akinlade","year":"2014","journal-title":"Int. Arch. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e011089","DOI":"10.1161\/JAHA.118.011089","article-title":"Lower Hospitalization and Healthcare Costs With Sacubitril\/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure","volume":"8","author":"Albert","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jacc.2015.02.009","article-title":"Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations","volume":"65","author":"Asgar","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e006740","DOI":"10.1161\/JAHA.117.006740","article-title":"Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)","volume":"7","author":"Bhatt","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e005565","DOI":"10.1161\/CIRCHEARTFAILURE.118.005565","article-title":"Sacubitril\/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts","volume":"12","author":"Burke","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"B7","first-page":"88","article-title":"Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with midrange ejection fraction","volume":"39","author":"Cunfang Chen","year":"2020","journal-title":"Chin J New Drugs Clin Rem"},{"key":"B8","first-page":"416","article-title":"Clinical effect of sacubitril\/valsartan for heart failure with mid- range ejection fraction in left ventricle","volume":"36","author":"Dongruil Xu","year":"2021","journal-title":"Clinical Focus"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.jacc.2014.07.978","article-title":"The heterogeneity of heart failure: will enhanced phenotyping be necessary for future clinical trial success?","volume":"64","author":"Francis","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.17219\/acem\/145664","article-title":"Efficacy and safety of sacubitril\/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome","volume":"31","author":"Fr\u00f6b","year":"2022","journal-title":"Adv. Clin. Exp. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2013.10.005","article-title":"Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure","volume":"2","author":"Gaggin","year":"2014","journal-title":"JACC. Heart Fail."},{"key":"B12","doi-asserted-by":"publisher","first-page":"E1897","DOI":"10.3390\/jcm9061897","article-title":"Sacubitril\/Valsartan Improves Autonomic Function and Cardiopulmonary Parameters in Patients with Heart Failure with Reduced Ejection Fraction","volume":"9","author":"Giallauria","year":"2020","journal-title":"J. Clin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.jacc.2018.02.059","article-title":"Domain Management Approach to Heart Failure in the Geriatric Patient: Present and Future","volume":"71","author":"Gorodeski","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"B16","first-page":"135","article-title":"Clinical effect of sacubitril valsartan in treating heart failure patients with mid-range ejection fraction","volume":"32","author":"He Wen","year":"2020","journal-title":"Chin Heart J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/eurheartj\/ehm102","article-title":"Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES)","volume":"28","author":"Hobbs","year":"2007","journal-title":"Eur. Heart J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"B19","doi-asserted-by":"publisher","first-page":"736208","DOI":"10.3389\/fcvm.2021.736208","article-title":"The Role of 6-Minute Walk Test Guided by Impedance Cardiography in the Rehabilitation Following Knee Arthroplasty: A Randomized Controlled Trial","volume":"8","author":"Lin","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B20","first-page":"139","article-title":"Comparative efficacy of renin-angiotensin aldesteron system modulators and angiotensin receptor neprilyzin inhibitor in chronic heart failure with mid-ranged and preserved ejection fraction","volume":"21","author":"Lr Liana Tumasyan","year":"2019","journal-title":"European Society of Cardiology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Maddox","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B22","first-page":"596","article-title":"Effect of angiotensin receptor neprilysin inhibitor on prognosis of patients with heart failure and mid-range ejection fraction","volume":"33","author":"Man Gao","year":"2021","journal-title":"Chin Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"Mcdonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"B24","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"Mcmurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B25","first-page":"540","article-title":"The effects of sacubitri-valsartan in heart failure patients with mid-range ejection fraction","volume":"29","author":"Meixian Chen","year":"2021","journal-title":"Chin J Hypertens"},{"key":"B26","first-page":"40","article-title":"Observation on the Effect of Sakubatrovalsartan in the Treatment of Heart Failure with Mid-range Ejection Fraction","volume":"28","author":"Mi","year":"2021","journal-title":"Chinese Practical Journal of Rural Doctor"},{"key":"B27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jchf.2018.02.006","article-title":"Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction","volume":"6","author":"Napier","year":"2018","journal-title":"JACC. Heart Fail."},{"key":"B28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.aucc.2009.06.001","article-title":"The role of b-type natriuretic peptide in heart failure management","volume":"22","author":"Newton","year":"2009","journal-title":"Aust. Crit. Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.hlc.2020.10.012","article-title":"The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis","volume":"30","author":"Nie","year":"2021","journal-title":"Heart Lung Circ."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/ehf2.13940","article-title":"The benefits of the earlier use of sacubitril\/valsartan in de novo heart failure with reduced ejection fraction patients","volume":"9","author":"Oh","year":"2022","journal-title":"ESC Heart Fail."},{"key":"B31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1056\/NEJMoa1807365","article-title":"Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy","volume":"381","author":"Panza","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"754499","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review","volume":"8","author":"Pascual-Figal","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3B","DOI":"10.1016\/j.amjcard.2015.01.034","article-title":"The biology of ST2: the International ST2 Consensus Panel","volume":"115","author":"Pascual-Figal","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"B34","first-page":"54","article-title":"Efficacy and safety of sacubitril valsartan in the treatment of patients with heart failure with midrange ejection fraction","volume":"5","author":"Pengfei Ma","year":"2020","journal-title":"Clinical medicine research and practice"},{"key":"B35","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"","journal-title":"Eur. J. Heart Fail."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.rec.2016.11.005","article-title":"2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"69","author":"Ponikowski","year":"","journal-title":"Rev. Esp. Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.798","article-title":"Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)","volume":"19","author":"Rickenbacher","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"B38","first-page":"544","article-title":"Short-term clinical efficacy of Sacubitril valsartan sodium in the treatment of heart failure with median ejection fraction irShort-term clinical efficacy of Sacubitril valsartan sodium in the treatment of heart failure with median ejection fraction irischemic cardiomyopathy","volume":"48","author":"Rong Liu","year":"2020","journal-title":"Clin J Med Offic"},{"key":"B39","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3389\/fphys.2018.00758","article-title":"Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome","volume":"9","author":"Sardu","year":"2018","journal-title":"Front. Physiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"106303","DOI":"10.1016\/j.phrs.2022.106303","article-title":"Angiotensin receptor\/Neprilysin inhibitor effects in CRTd non-responders: From epigenetic to clinical beside","volume":"182","author":"Sardu","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Solomon","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11897-019-00451-0","article-title":"Heart Failure With Mid-range Ejection Fraction","volume":"17","author":"Srivastava","year":"2020","journal-title":"Curr. Heart Fail. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamacardio.2019.4982","article-title":"Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril\/Valsartan and Ivabradine in Heart Failure","volume":"5","author":"Sumarsono","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1753944719840192","DOI":"10.1177\/1753944719840192","article-title":"A comprehensive review of chronic heart failure pharmacotherapy treatment approaches in African Americans","volume":"13","author":"Tillman","year":"2019","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e015640","DOI":"10.1161\/JAHA.119.015640","article-title":"Sacubitril\/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model","volume":"9","author":"Vaskova","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"B49","doi-asserted-by":"publisher","first-page":"E262","DOI":"10.3390\/jcm8020262","article-title":"Early Effects of Sacubitril\/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction","volume":"8","author":"Vitale","year":"2019","journal-title":"J. Clin. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial","volume":"7","author":"Wachter","year":"2020","journal-title":"ESC Heart Fail."},{"key":"B51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12906-019-2595-4","article-title":"The extract from Agkistrodon halys venom protects against lipopolysaccharide (LPS)-induced myocardial injury","volume":"31","author":"Wang","year":"2019","journal-title":"BMC Complement. Altern. Med."},{"key":"B52","first-page":"1015","article-title":"Effect of sacubitril\/valsartan on LVEF and remodeling in elderly patients with HFmrEF","volume":"23","author":"Wu Yi","year":"2021","journal-title":"Chin J Geriatr Heart Brain Vessel Ds"},{"key":"B53","first-page":"46","article-title":"A Clinical Study of the Efficacy and Safety of Sacubitril-valsartan in the Treatment of Patients with Median Ejection Fraction Heart Failure","volume-title":"World Latest Medicine Information (Electronic Version)","author":"Xiang Li","year":"2021"},{"key":"B54","first-page":"1689","article-title":"Effects of shakubatrovalsartan on cardiac function and near - term prognosis in patients with median ejection fraction heart failure","volume":"20","author":"Xiangjie Liu","year":"2021","journal-title":"Journal of Clinical and Experimental Medicin"},{"key":"B55","doi-asserted-by":"publisher","first-page":"68","DOI":"10.14744\/AnatolJCardiol.2018.38364","article-title":"The impact of heart rate on patients diagnosed with heart failure with mid-range ejection fraction","volume":"21","author":"Xin","year":"2019","journal-title":"Anatol. J. Cardiol."},{"key":"B56","first-page":"21","article-title":"Efficacy analysis of angiotensin receptor enkephalinase inhibitor to treat heart failure with mid-range e-jection fraction","volume":"40","author":"Xinxin Guo","year":"2021","journal-title":"Journal of Cardiovascular and Pulmonary Diseases"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.3389\/fphys.2018.01774","article-title":"Male Patients With Dilated Cardiomyopathy Exhibiting a Higher Heart Rate Acceleration Capacity or a Lower Deceleration Capacity Are at Higher Risk of Cardiac Death","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Physiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e28729","DOI":"10.1097\/MD.0000000000028729","article-title":"Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients","volume":"101","author":"Ye","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"B59","first-page":"132","article-title":"Effect of sacubitril\/valsartan on the prognosis of patients with heart failure with failure with midrange ejection fraction","volume":"37","author":"Yongyue Zhou","year":"2021","journal-title":"Journal of Clinical Cardiology( China)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1002\/ehf2.12974","article-title":"Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2020","journal-title":"ESC Heart Fail."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.982372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T08:05:59Z","timestamp":1666598759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.982372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":61,"alternative-id":["10.3389\/fphar.2022.982372"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.982372","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]},"article-number":"982372"}}